On this page
Erythromycin
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Erythromycin | 20 mg/g | 197650 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased Sebaceous Gland Activity [PE] | PE | All 37 members |
| Macrolide Antimicrobial [EPC] | EPC | All 31 members |
| Macrolide [EPC] | EPC | All 16 members |
| Macrolides [CS] | CS | All 32 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 063211-001 | ERYTHROMYCIN | GEL | ERYTHROMYCIN | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 3 | Labeling | Approved | March 31, 2008 | — |
| Original application | 1 | Approved | January 29, 1993 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20230816). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Erythromycin Topical Gel USP, 2% is indicated for the topical treatment of acne vulgaris.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d. dosing.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Erythromycin Topical Gel USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In controlled clinical trials, the incidence of burning associated with erythromycin topical gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.
Description
openFDA Drug LabelingDESCRIPTION Erythromycin Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3- C -methyl-3- O -methyl-α-L- ribo -hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)-β-D- xylo -hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus ). It is a base and readily forms salts with acids. Chemically, erythromycin is C 37 H 67 NO 13 . It has the following structural formula: Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practically odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such as alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polar solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solvents such as hexane. It is very poorly soluble in water. Each gram of Erythromycin Topical Gel USP, 2% contains 20 mg of erythromycin USP in a vehicle consisting of dehydrated alcohol and hydroxypropyl cellulose. Chemical structure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Erythromycin Topical Gel USP, 2% is available as follows: 60 g sealed metal tube (NDC 63629-8653-1) Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ERYTHROMYCIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8652-1 | 63629-8652 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8652-1) / 30 g in 1 TUBE | September 8, 2008 |
| 63629-8653-1 | 63629-8653 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8653-1) / 60 g in 1 TUBE | June 12, 2008 |
| 72162-1444-3 | 72162-1444 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1444-3) / 30 g in 1 TUBE | August 16, 2023 |
| 72162-1444-6 | 72162-1444 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1444-6) / 60 g in 1 TUBE | August 16, 2023 |
| 45802-966-94 | 45802-966 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-966-94) / 30 g in 1 TUBE | September 8, 2008 |
| 45802-966-96 | 45802-966 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-966-96) / 60 g in 1 TUBE | June 12, 2008 |
| 63629-8652 | 63629-8652 | Bryant Ranch Prepack | — | June 12, 2008 |
| 63629-8653 | 63629-8653 | Bryant Ranch Prepack | — | June 12, 2008 |
| 72162-1444 | 72162-1444 | Bryant Ranch Prepack | — | June 12, 2008 |
| 45802-966 | 45802-966 | Padagis Israel Pharmaceuticals Ltd | — | June 12, 2008 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.